- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Fluoxetine benefits patients of refractory monosymptomatic nocturnal enuresis
Overview
Nocturnal enuresis is involuntary urination that happens at night while sleeping, after the age when a person should be able to control his or her bladder. Most of us think of bedwetting as something that happens with little kids.
For children and adolescents with refractory primary monosymptomatic nocturnal enuresis (PMNE), fluoxetine therapy, a selective serotonin reuptake inhibitor, is a safe therapeutic option that produces an initial positive response. A study that appeared in the Journal of Urology found that the response rate does, however, gradually decline with time.
For more details, check out the link given below:
Fluoxetine benefits patients of refractory monosymptomatic nocturnal enuresis
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)